MT-act

MT-act ambitions to become the leading company providing new chemical entities that safely restore the defects of the skeleton of our cells in chronic diseases We developed MT discover®, a unique modular discovery platform to extract an untapped pharmaceutical space named the ‘Tubulin Code’ The modular scalable platform delivered the first lead compound to become a transformative treatment. The company employs 6 FTEs and is hosted on the CNRS campus in Montpellier (France) granting access to cutting edge equipment and resources.